Kirsten Drejer
Director/Board Member at ZEALAND PHARMA A/S
Net worth: 876 309 $ as of 2024-03-30
Profile
Kirsten Aarup Drejer was the founder and had founded Symphogen A in 2000, where she held the title of Chief Executive Officer until 2016.
She currently holds multiple positions, including Vice Chairman at Zealand Pharma A since 2018, Chairman at Bioneer A, Antag Therapeutics ApS, and ResoTher Pharma AS, Independent Non-Executive Director at Malin Corp.
Plc since 2020, Director at Curasight A since 2021, and Director at The Danish Green Growth Fund and Lyhne & Co. Dr. Drejer has also held former positions as Director at International N&H Denmark ApS from 2006 to 2011, Independent Director at Bioporto A from 2017 to 2021, Independent Director at Alligator Bioscience AB from 2019 to 2021, Director at DTU Systems Biology and The Danish National Advanced Technology Foundation, Independent Non-Executive Director at Bionor Pharma ASA from 2015 to 2016, and Director-Diabetes Discovery at Novo Nordisk A from 1991 to 2000.
Dr. Drejer has an educational background, having graduated and obtained a doctorate from the University of Copenhagen, and an undergraduate degree from Danmarks Farmaceutiske Universitet.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ZEALAND PHARMA A/S
0.01% | 2023-12-30 | 8,800 ( 0.01% ) | 870 017 $ | 2024-03-30 |
CURASIGHT A/S
0.02% | 2022-12-30 | 3,979 ( 0.02% ) | 6 292 $ | 2024-03-30 |
Kirsten Drejer active positions
| Companies | Position | Start |
|---|---|---|
| ZEALAND PHARMA A/S | Director/Board Member | 2018-04-18 |
| MALIN CORPORATION PLC | Director/Board Member | 2020-03-23 |
| CURASIGHT A/S | Director/Board Member | 2021-05-03 |
Bioneer A/S
 Bioneer A/S Pharmaceuticals: MajorHealth Technology Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark. | Chairman | - |
| The Danish Green Growth Fund | Director/Board Member | - |
| Lyhne & Co. | Director/Board Member | - |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Chairman | - |
Antag Therapeutics ApS
 Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | Chairman | - |
Former positions of Kirsten Drejer
| Companies | Position | End |
|---|---|---|
| ALLIGATOR BIOSCIENCE AB | Director/Board Member | 2021-05-31 |
| ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Kirsten Drejer
| University of Copenhagen | Doctorate Degree |
| Danmarks Farmaceutiske Universitet | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| MALIN CORPORATION PLC | Health Technology |
| BIOPORTO A/S | Health Technology |
| ALLIGATOR BIOSCIENCE AB | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| CURASIGHT A/S | Health Technology |
| Private companies | 10 |
|---|---|
International N&H Denmark ApS
 International N&H Denmark ApS Food: Major DiversifiedConsumer Non-Durables DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark | Consumer Non-Durables |
Bioneer A/S
Bioneer A/S Pharmaceuticals: MajorHealth Technology Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark. | Health Technology |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
| DTU Systems Biology | |
The Danish National Advanced Technology Foundation
 The Danish National Advanced Technology Foundation Financial ConglomeratesFinance The Danish National Advanced Technology Foundation promotes research and innovation by providing funds. It offers private companies and universities the funds and the framework for developing new and important technologies. The company was founded in 2005 and is headquartered in Copenhagen, Denmark. | Finance |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |
| The Danish Green Growth Fund | Miscellaneous |
Antag Therapeutics ApS
Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | Health Technology |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Health Technology |
| Lyhne & Co. |
- Stock Market
- Insiders
- Kirsten Drejer
